Author:
Lorenzatti Alberto,Servato Maria Luz, , ,
Abstract
Coronary artery disease (CAD) is the leading cause of death worldwide. Despite notable advances in understanding the nature of atherosclerotic processes and the use of effective medications such as statins, there remains a significant residual risk. Even after optimal medical treatments and precise revascularisations, the recurrence of MI remains at approximately one-third for 5 years after an acute coronary syndrome (ACS). Over the past two decades, compelling data from animal and human studies has clearly identified atherosclerosis as an inflammatory disease of the arterial wall, but clinical applications related to this accumulated knowledge are still scarce. Recently, the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS) has provided convincing evidence that an anti-inflammatory intervention with the monoclonal antibody canakinumab reduces cardiovascular events in well-treated CAD patients without affecting LDL cholesterol levels. This article presents a brief description of the role of inflammation in atherogenesis and examines selected anti-inflammatory interventions and their potential use in CAD-affected individuals.
Subject
Cardiology and Cardiovascular Medicine
Reference33 articles.
1. A consensus statement from the European Atherosclerosis Society Consensus Panel;Ference;Eur Heart J,2017
2. 2. World Health Organization. Global Health Observatory Data Repository - Mortality and burden of disease - WHO regions. Geneva: WHO, 2008.
3. A prospective natural-history study of coronary atherosclerosis;Stone;N Engl J Med,2011
4. 4. Virchow R, Osler W, Welch WH. Cellular Pathology. Omaha, NE: Gryphon Editions/Classics of Medicine Library, 1978.
5. Atherosclerosis - an inflammatory disease;Ross;N Engl J Med,1999
Cited by
16 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献